ロード中...
FGF19 protects skeletal muscle against obesity‐induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT‐1/PGC‐α pathway
Obesity is associated with biological dysfunction in skeletal muscle. As a condition of obesity accompanied by muscle mass loss and physical dysfunction, sarcopenic obesity (SO) has become a novel public health problem. Human fibroblast growth factor 19 (FGF19) plays a therapeutic role in metabolic...
保存先:
| 出版年: | J Cell Mol Med |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8034456/ https://ncbi.nlm.nih.gov/pubmed/33751819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.16448 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|